Welcome to



Your source for up to date information on the development of experimental plasmalogen replacement drug PPI-1040 for the treatment of RCDP.

LATEST NEWS: Sept 5 2019. FDA Grants PPI-1040 Orphan Drug Designation


Learn what RCDP is and what causes it, including a plasmalogen primer.

Learn more about the plasmalogen replacement drug PPI-1040.

Learn why collecting baseline data on RCDP children is critical.


Go here for more information about the preclinical and clinical development plans.

Here you will find a library of resources relating to RCDP and plasmalogens.

Find the latest updates about the trial here.